Home › Major Depressive Disorder › NCT05645575
In-patient SCC TMS
Pilot Study: Evaluating the Feasibility of Accelerated rTMS Treatment Delivered at Individual Resonant Frequencies for In-patient Subjects Suffering From Major Depressive Disorder
Who can join
Ages 18 to 65 · All sexes
Full eligibility criteria
Inclusion Criteria: 1. All subjects must be between 18-65 years of age. 2. Must have confirmed diagnosis of moderate to severe Major Depressive Disorder (single or recurrent episode) as defined by a HAM-D score of 17 or higher. 3. Failure to respond to a minimum of 2 trials of antidepressant medication 4. Failure to respond from at least two different agent classes 5. Accompanied by at least two evidence-based augmentation therapies (Benzodiazepines do not count). 6. Must have a trial of psychotherapy known to be effective in the treatment of MDD of an adequate frequency and duration. 7. Subjects are willing and able to adhere to the accelerated treatment schedule. Exclusion Criteria: 8. Are mentally or legally incapacitated, unable to give informed consent 9. Have an infection or poor skin condition over the scalp where the device will be positioned 10. Have increased risk of seizure because of family history, stroke, or currently use medications that lead to increased risk for seizure 11. Diagnosis of acute or chronic psychotic symptoms or disorders (such as schizophrenia, schizophreniform or schizoaffective disorder) in the current depressive episode. 12. Neurological conditions that include epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, having a history of repetitive or severe head trauma, or with primary or secondary tumors in the central nervous system. 13. Presence of an implanted magnetic-sensitive medical device present in the body scan, including but not limited to a cochlear implant, implanted cardioverter defibrillator, pacemaker, vagus nerve stimulator, or metal aneurysm clips or coils, staples, or stents. (Note: Dental amalgam fillings are not affected by the magnetic field and are acceptable for use with transcranial magnetic stimulation and MRI.)
About the study
The investigators are studying the feasibility, safety, and tolerability of administering accelerated repetitive Transcranial magnetic stimulation(a-rTMS) at frequencies other than standard 10 Hz for in-patient Subjects diagnosed with Major Depressive Disorder. Participants will be recruited from the Resnick Neuropsychiatric Hospital. This study will enroll 30 participants who will undergo up to three brain activity recordings, one MRI scan, one TMS procedure to determine the appropriate frequency and intensity for treatment, daily symptom assessments, and 25 TMS treatments. Participants will be asked to participate for up to 2 weeks.
What is being tested
- Open-label TMS (device)
Sponsor: University of California, Los Angeles · Participants: 30 · Started: Apr 1, 2025
Contact the study team
- Nikita Vincecruz, BS · Phone: 310-825-4781
Official record on ClinicalTrials.gov — NCT05645575
Locations in the U.S.
| California | UCLA TMS Service and Research Service, Los Angeles |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.